Literature DB >> 31589041

Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy.

Dennis J Worm1, Paul Hoppenz1, Sylvia Els-Heindl1, Martin Kellert2, Robert Kuhnert2, Stefan Saretz2, Johannes Köbberling3, Bernd Riedl3, Evamarie Hey-Hawkins2, Annette G Beck-Sickinger1.   

Abstract

G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with the bound ligand. This mechanism was exploited to shuttle boron atoms into cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach to eliminate cancer cells. A maximized number of carboranes was introduced to the hY1R-preferring ligand [F7,P34]-NPY by solid phase peptide synthesis. Branched conjugates loaded with up to 80 boron atoms per peptide molecule exhibited a maintained receptor activation profile, and the selective uptake into hY1R-expressing cells was demonstrated by internalization studies. In order to ensure appropriate solubility in aqueous solution, we proved the need for eight hydroxyl groups per carborane. Thus, we suggest the utilization of bis-deoxygalactosyl-carborane building blocks in solid phase peptide synthesis to produce selective boron delivery agents for BNCT.

Entities:  

Year:  2019        PMID: 31589041     DOI: 10.1021/acs.jmedchem.9b01136

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Boron Neutron Capture Therapy: Current Status and Challenges.

Authors:  Song Wang; Zhengchao Zhang; Lele Miao; Yumin Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

2.  A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation.

Authors:  Alessandro Rondina; Paola Fossa; Alessandro Orro; Luciano Milanesi; Antonella De Palma; Davide Perico; Pier Luigi Mauri; Pasqualina D'Ursi
Journal:  Cells       Date:  2021-11-18       Impact factor: 6.600

Review 3.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

Review 4.  Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment.

Authors:  Dominika Skwierawska; José Antonio López-Valverde; Marcin Balcerzyk; Antonio Leal
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

Review 5.  Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.

Authors:  Paul Hoppenz; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Front Chem       Date:  2020-07-07       Impact factor: 5.221

6.  Improving Membrane Activity and Cargo Delivery Efficacy of a Cell-Penetrating Peptide by Loading with Carboranes.

Authors:  Tamara Lützenburg; Nele Burdina; Matthias S Scholz; Ines Neundorf
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

7.  Boron rich nanotube drug carrier system is suited for boron neutron capture therapy.

Authors:  Fabian Heide; Matthew McDougall; Candice Harder-Viddal; Roy Roshko; David Davidson; Jiandong Wu; Camila Aprosoff; Aniel Moya-Torres; Francis Lin; Jörg Stetefeld
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.